[go: up one dir, main page]

AR026037A1 - INDOLINONES REPLACED IN POSITION 5, ITS PREPARATION AND ITS USE AS MEDICATIONS - Google Patents

INDOLINONES REPLACED IN POSITION 5, ITS PREPARATION AND ITS USE AS MEDICATIONS

Info

Publication number
AR026037A1
AR026037A1 ARP000105395A ARP000105395A AR026037A1 AR 026037 A1 AR026037 A1 AR 026037A1 AR P000105395 A ARP000105395 A AR P000105395A AR P000105395 A ARP000105395 A AR P000105395A AR 026037 A1 AR026037 A1 AR 026037A1
Authority
AR
Argentina
Prior art keywords
preparation
indolinones
medications
replaced
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP000105395A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR026037A1 publication Critical patent/AR026037A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El presente se refiere a indolinonas sustituidas en posicion 5 de la formula general (1) en la que R1 hasta R5 y X están definidos como en lareivindicacion 1, sus isomeros y sus sales, especialmente sus sales fisiologicamente compatibles, quepresent an valiosas propiedades farmacologicas,especialmente un efecto inhibidor sobre diferentes quinasas y complejos de ciclinas y CDKs sobre tirosina-quinasa de receptores, así como sobre laproliferacion de células de tumores, a medicamentos quecontienen estos compuestos, a su utilizacion y a procedimientos para su preparacion.This refers to indolinones substituted in position 5 of the general formula (1) in which R1 to R5 and X are defined as in claim 1, their isomers and their salts, especially their physiologically compatible salts, which have valuable pharmacological properties, especially an inhibitory effect on different kinases and complexes of cyclines and CDKs on receptor tyrosine kinase, as well as on the proliferation of tumor cells, medications containing these compounds, their use and procedures for their preparation.

ARP000105395A 1999-10-13 2000-10-13 INDOLINONES REPLACED IN POSITION 5, ITS PREPARATION AND ITS USE AS MEDICATIONS Pending AR026037A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19949209A DE19949209A1 (en) 1999-10-13 1999-10-13 5-substituted indolinones, their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
AR026037A1 true AR026037A1 (en) 2002-12-26

Family

ID=7925398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105395A Pending AR026037A1 (en) 1999-10-13 2000-10-13 INDOLINONES REPLACED IN POSITION 5, ITS PREPARATION AND ITS USE AS MEDICATIONS

Country Status (6)

Country Link
EP (1) EP1224169A2 (en)
AR (1) AR026037A1 (en)
AU (1) AU7663100A (en)
CO (1) CO5261507A1 (en)
DE (1) DE19949209A1 (en)
WO (1) WO2001027080A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
EP1458713B1 (en) 2001-12-27 2005-08-24 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
DE10237423A1 (en) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE102004012068A1 (en) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceuticals
DE102004012070A1 (en) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
JP2009533480A (en) * 2006-04-24 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 3- (Aminomethylidene) 2-indolinone derivatives and their use as cytostatics
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
MX2021003945A (en) * 2018-10-05 2021-05-27 Ichnos Sciences S A Indolinone compounds for use as map4k1 inhibitors.
CN111285872B (en) * 2018-12-06 2022-05-17 北京志健金瑞生物医药科技有限公司 Indole-2-ketone derivative and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476307A (en) * 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (en) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma New substituted indolinones, their production and their use as medicines

Also Published As

Publication number Publication date
WO2001027080A3 (en) 2001-11-22
DE19949209A1 (en) 2001-04-19
WO2001027080A2 (en) 2001-04-19
AU7663100A (en) 2001-04-23
EP1224169A2 (en) 2002-07-24
CO5261507A1 (en) 2003-03-31

Similar Documents

Publication Publication Date Title
AR026036A1 (en) INDOLINONES REPLACED IN POSITION 6, ITS PREPARATION AND ITS USE AS MEDICATIONS
AR026037A1 (en) INDOLINONES REPLACED IN POSITION 5, ITS PREPARATION AND ITS USE AS MEDICATIONS
AR025389A1 (en) INDOLINONES REPLACED, THEIR PREPARATION AND THEIR EMPLOYMENT AS MEDICATIONS
CL2008001230A1 (en) Compounds derived from pyrrole (2.3-d) pyrimidine. purin-6-yl or pyrazol (3,4-d) pyrimldine, p70 s6 kinase inhibitors; pharmaceutical composition; and use for the preparation of drugs useful in the treatment of colon adenocarcinomas and inhibition of angiogenesis.
ECSP034776A (en) INDOLINONES REPLACED IN POSITION 6, ITS PREPARATION AND ITS USE AS MEDICATIONS
CL2008000020A1 (en) Compounds derived from substituted 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and malignant tumors.
ECSP099821A (en) METABOLITES OF THE JANUS QUINASA INHIBITOR (R) -3- (4- (7H-PIRROLO [2,3-d] PIRIMIDIN-4-IL) -1H-PIRAZOL-1-IL) -3-CYCLOPENTILPROPANONITRILE
CU20090213A7 (en) JANUS CINASA INHIBITOR SALTS (R) -3- (4- (7H-PIRROLO [2,3-D] PIRIMIDIN-4-IL) -1H-PIRAZOL-1-IL) -3-CICLOPENTILPROPANITRILO
NI201000050A (en) DERIVATIVES OF PIRROLO [2, 3-D] PYRIMIDINE AS INHIBITORS OF PROTEIN KINASES B.
BRPI0507644A (en) pyrazolopyrimidines as cyclin-dependent kinase inhibitors
ES2196860T3 (en) NEW INDOLINONES REPLACED WITH INHIBITING EFFECT ON DIFFERENT KINASES AND DIFFERENT COMPLEX CYCLINE / CDK.
ES2192877T3 (en) 4-ALQUENIL (AND ALQUINIL) OXINDOLS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES, IN PARTICULAR CDK2.
GT200100061A (en) PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AND METHODS TO INHIBIT PROTEIN KINASES.
ECSP109957A (en) DERIVATIVES OF PIRIMIDINIL-PIRIDAZINONA.
CU20110137A7 (en) DERIVATIVES OF INDIR PYRIMIDIN FOR CANCER TREATMENT
CL2008002243A1 (en) Compounds derived from 2-pyrazolamino-1,3,5-triazine, jak kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment of cancer.
NZ788005A (en) Inhibitors of raf kinases
TR200002980T2 (en) Substituted indolinones with inhibitory effect
CL2011000489A1 (en) Compounds derived from pyrimido [5,4-d] pyrimidine, which act as tyrosine kinase inhibitors; and pharmaceutical compositions that comprise them, useful in the treatment of diseases characterized by excessive or abnormal cell proliferation
BRPI0517921A (en) methods for preparing indazole compounds
MX2010004017A (en) 5-cyano-thienopyridines for the treatment of tumors.
UY27903A1 (en) INDOLINONA DERIVATIVES SUBSTITUTED IN POSITION 6, ITS PREPARATION AND ITS USE AS MEDICINES.
GT200200190A (en) SUBSTITUTED BENZIMIDAZOL COMPOUNDS AND ITS USE IN CANCER TREATMENT
ECSP099562A (en) BICYCLIC HETEROCICLES, MEDICATIONS CONTAINING THESE COMPOUNDS, ITS USE AND PROCEDURES FOR THEIR PREPARATION
UY26988A1 (en) NEW INDOLINONES REPLACED, ITS PREPARATION AND ITS USE AS MEDICINES.